Podcast: Spray Away Severe Depression
Dr. Caleb Battersby, UConn Health's director of interventional psychiatry, explains a treatment approach to severe depression that's providing hope
A form of ketamine delivered as a nasal spray is showing effectiveness in treating severe depression. The FDA has approved esketamine for adults with treatment-resistant depression; the patient self-administers it in a supervised clinical setting.
Dr. Caleb Battersby, director of interventional psychiatry at UConn Health, joins the UConn Health Pulse podcast to explain how it works and why it’s providing hope for patients who haven’t had success with other treatments.
It can translate into people being able to kind of make lifestyle changes probably more quickly and more effectively than they do with oral medications. — Dr. Caleb Battersby
Listen now:
Latest UConn Today
- Neag School Class of 2025 Student Profile: Michael Santos“Choosing UConn felt natural ... because of the wide range of academic and experiential opportunities available to students here.”
- Neag School Class of 2025 Student Profile: Sara Rosenthal“I knew that UConn had so many different groups of people, and I was positive that I would eventually find the place where I belonged within the community.”
- UConn Equestrian Team Achieves Highest Points in Region“I found my people and a true home. I’m just lucky to get to ride horses every week and be with such a great group of people."
- Sending off the Class of 2025The School of Dental Medicine celebrated the accomplishments of fourth-year students ahead of commencement
- After the Storm, a Rainbow for Cancer SurvivorsUConn Health Carole and Ray Neag Cancer Center Celebrates Survivors at the Yard Goats Game
- Building Awareness of Ethical Animal ResearchOn April 17, UConn researchers took part in Biomedical Research Awareness Day.
